Developing an Ethics and Policy Framework for Psychedelic Clinical Care: A Consensus Statement.

Autor:	McGuire AL; Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston, Texas., Cohen IG; Petrie-Flom Center for Health Law Policy, Biotechnology & Bioethics, Harvard Law School, Cambridge, Massachusetts., Sisti D; Department of Medical Ethics and Health Policy, University of Pennsylvania, Philadelphia., Baggott M; Tactogen Inc, Palo Alto, California., Celidwen Y; Othering and Belonging Institute, Department of Psychology, University of California Berkeley., Devenot N; Johns Hopkins University, Baltimore, Maryland., Gracias S; Ortus Foundation, Jackson, Wyoming., Grob C; Harbor-UCLA Medical Center, Torrance, California., Harvey I; People of Color Psychedelic Collective, New York, New York., Kious B; Department of Psychiatry, University of Utah Health, Salt Lake City., Marks M; Florida State University College of Law, Tallahassee., Mithoefer M; Multidisciplinary Association for Psychedelic Studies (MAPS) Public Benefit Corporation, New York, New York., Nielson E; Fluence Training, New York, New York., Öngür D; McLean Hospital, Harvard Medical School, Boston, Massachusetts., Pallas A; Beckley Retreats, Frederick, Maryland., Peterson A; Department of Philosophy, George Mason University, Fairfax, Virginia., Schenberg EE; Instituto Phaneros, Brazil., Summergrad P; Departments of Psychiatry and Medicine, Tufts University School of Medicine, Boston, Massachusetts., Waters B; Reason for Hope, New York, New York., Williams MT; School of Psychology & Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada., Yaden DB; Center for Psychedelic and Consciousness Research, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Jazyk:	angličtina
Zdroj:	JAMA network open [JAMA Netw Open] 2024 Jun 03; Vol. 7 (6), pp. e2414650. Date of Electronic Publication: 2024 Jun 03.
DOI:	10.1001/jamanetworkopen.2024.14650
Abstrakt:	Importance: As government agencies around the globe contemplate approval of the first psychedelic medicines, many questions remain about their ethical integration into mainstream medical practice. Objective: To identify key ethics and policy issues related to the eventual integration of psychedelic therapies into clinical practice. Evidence Review: From June 9 to 12, 2023, 27 individuals representing the perspectives of clinicians, researchers, Indigenous groups, industry, philanthropy, veterans, retreat facilitators, training programs, and bioethicists convened at the Banbury Center at Cold Spring Harbor Laboratory. Prior to the meeting, attendees submitted key ethics and policy issues for psychedelic medicine. Responses were categorized into 6 broad topics: research ethics issues; managing expectations and informed consent; therapeutic ethics; training, education, and licensure of practitioners; equity and access; and appropriate role of gatekeeping. Attendees with relevant expertise presented on each topic, followed by group discussion. Meeting organizers (A.L.M., I.G.C., D.S.) drafted a summary of the discussion and recommendations, noting points of consensus and disagreement, which were discussed and revised as a group. Findings: This consensus statement reports 20 points of consensus across 5 ethical issues (reparations and reciprocity, equity, and respect; informed consent; professional boundaries and physical touch; personal experience; and gatekeeping), with corresponding relevant actors who will be responsible for implementation. Areas for further research and deliberation are also identified. Conclusions and Relevance: This consensus statement focuses on the future of government-approved medical use of psychedelic medicines in the US and abroad. This is an incredibly exciting and hopeful moment, but it is critical that policymakers take seriously the challenges ahead.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu